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Abstract
Subarachnoid haemorrhage (SAH) occurs as a result of rupture of intracra-
nial aneurysms. SAH causes significant morbidity and mortality. In addition, 
SAH leads to significant financial burden. In this chapter, we will look into the 
association between raised serum homocysteine and intracranial aneurysms. 
In a study on the Han Chinese patients with intracranial aneurysm who were 
admitted to the hospital, the mean serum total homocysteine level in the patient 
group with intracranial aneurysm was significantly higher than those in the 
control group. In the same study, the patients with raised serum homocysteine 
had 2.196 higher risk of developing intracranial aneurysms. Ren et al. proposed 
that homocysteine should be seen as an indicator of the risk of intracranial 
aneurysm and not a direct cause of intracranial aneurysm. In another study, 
homocysteine increases the development of intracranial aneurysms in rats. 
Endothelial damage is an early change in the walls of intracranial aneurysms. 
Polymorphisms of the genes coding for the various components of the vessel 
walls may be associated with the formation of intracranial aneurysms. In a pre-
vious animal study, the size of intracranial aneurysms is significantly smaller in 
the mice with inducible nitric oxide synthase (iNOS) compared with the mice 
without iNOS.
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1. Introduction
1.1 Subarachnoid haemorrhage
Subarachnoid haemorrhage (SAH) is caused by rupture of intracranial aneu-
rysms [1, 2]. Approximately 5–15% of the stroke patients have ruptured intracranial 
aneurysms [3, 4].
Aneurysmal SAH leads to a prolonged hospital stay [1]. Therefore, aneurysmal 
subarachnoid haemorrhage results in a significant financial burden in the USA [1]. In 
addition, aneurysmal SAH causes approximately 45% mortality in 30 days [3, 5]. As 
many as 30% of the patients who survived the SAH had moderate to severe neuro-
logical deficit and disability [3, 5].
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1.2 Intracranial aneurysms
Saccular intracranial aneurysms are abnormal focal outpouchings of cerebral 
arteries [3]. The prevalence of intracranial aneurysms in the adult population in the 
USA is 1–5% [3, 6]. Most of the intracranial aneurysms are small [3]. Approximately 
50–80% of all the intracranial aneurysms do not rupture [3, 7].
Intracranial aneurysms are usually sporadically acquired lesions [3]. A rare 
familial form is present, and this is associated with conditions such as cerebral 
arteriovenous malformations (AVMs), autosomal dominant polycystic kidney 
disease (ADPKD), fibromuscular dysplasia, Marfan syndrome and Ehlers-Danlos 
syndrome [3, 5]. Multiple genetic susceptibilities may be acting synergistically in 
the development of SAH [5, 8]. The increase in the familial risk of developing SAH 
is nearly four times higher among first-degree relatives [5, 9, 10].
Unruptured aneurysms can potentially result in cranial nerve palsies such as 
third cranial nerve palsy and rarely brainstem compression [3, 7, 11]. These patients 
have a higher risk of rupture of intracranial aneurysm [3, 7]. They have an annual 
risk of aneurysmal rupture of about 6% [3, 12].
1.3 Homocysteine
Homocysteine is an endogenous, nonstructural protein which contains sulphur 
[13]. Homocysteine is involved in the metabolism pathway of methionine and 
cysteine [13, 14]. Homocysteine can be irreversibly degraded to cysteine via the 
trans-sulphuration pathway or remethylated back to methionine [15]. The bio-
chemistry of methionine is regulated by the enzymes controlling homocysteine 
concentration [15]. An elevated level of serum homocysteine is the intermediate 
product of methionine metabolism [16].
In addition, the metabolism of homocysteine is dependent on nutritional 
factors comprising of vitamin B12 and folic acid [16, 17]. A reduction in the levels 
of vitamin B12 and folic acid causes an increase in serum homocysteine levels [16]. 
Homocysteine also plays an important role in the metabolism of folic acid and 
catabolism of choline which are both vital for the regulation of methionine [15]. 
Homocysteine is very important for the cellular homeostasis [15].
Normal level of total concentration of homocysteine in plasma of healthy people 
is between 5.0 and 15.0 mmol/l. [13] Raised serum homocysteine is an independent 
risk factor for cardiovascular diseases [13, 15, 18]. Elevated serum homocysteine is 
associated with a rise in morbidity and mortality [18, 19].
An increase in serum homocysteine results in oxidative stress and systemic 
inflammation which in turn leads to an accelerated telomere shortening [13, 19]. 
Furthermore, elevated serum homocysteine damages endothelial cells [13]. As a 
result, the blood vessels are less flexible and the process of haemostasis is disturbed 
[13]. An increase in serum homocysteine can be treated by folic acid, vitamin 
B12 and vitamin B6 supplements [13, 15].
2. Homocysteine and intracranial aneurysm
Ren et al. conducted a study on the Han Chinese patients with intracranial aneu-
rysm who were admitted to the hospital [17]. In this study, the mean serum total 
homocysteine level in the patient group with intracranial aneurysm was significantly 
higher than those in the control group [17]. In addition, homocysteine had an adjusted 
odds ratio of 2.196 (P = 0.012) for the development of intracranial aneurysm [17].
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Furthermore, raised serum homocysteine was reported to be an independent 
risk factor for development of intracranial aneurysms [17]. Ren et al. proposed that 
homocysteine should be seen as an indicator of the risk of intracranial aneurysm 
and not a direct cause of intracranial aneurysm [17].
In the same study, an association between serum total homocysteine and folate 
and vitamin B12 in the patients with intracranial aneurysm was present [17]. The 
serum total homocysteine level was negatively correlated with folate and vitamin 
B12 levels in the study by Ren et al. [17] Folic acid and vitamin B12 are therefore 
found to be protective against formation of intracranial aneurysms [17]. This is 
due to the roles of vitamin B12 and folic acid in the regulation of the metabolism of 
homocysteine [17]. In a previous study, insufficient plasma level of one or more B 
vitamins may potentially result in high levels of serum homocysteine [16].
In the study conducted by Xu et al., homocysteine increases the development of 
intracranial aneurysms in rats, possibly by the different effects on the expression 
of molecules which are essential for vascular wall modeling [20]. The formation of 
intracranial aneurysms is associated with chronic inflammation [20].
Endothelial damage is one of the early changes in the walls of intracranial 
aneurysms resulting from inflammation [20]. An increase in serum homocysteine 
has been reported to damage the vascular endothelium [20]. This in turn leads to 
the development of atherosclerosis [20].
3. Polymorphism
Interestingly, polymorphism of the genes coding for the various components of 
the vessel walls has been proposed to be associated with the development of intra-
cranial aneurysms [5, 8].
Polymorphisms involving homocysteine metabolism can also promote formation 
of abdominal aortic aneurysms, dissection of the cervical arteries and atherosclero-
sis [5, 21, 22].
Moreover, the expression of matrix metalloproteinase-2 (MMP-2), endothelial 
nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and 
MMP-2 in the walls of intracranial aneurysm was increased by methionine treat-
ment in Xu et al.’s study [20].
Furthermore, autosomal recessive deficiency in cystathionine-synthase is 
involved in homocysteine metabolism [5, 23]. This deficiency in cystathionine-
synthase presents together with the development of intracranial aneurysms [5, 23].
In the study by Semmler et al., polymorphisms of homocysteine metabolism are 
possible risk factors for the formation of intracranial aneurysms [5]. The G-allele of 
RFC1c.80G→A and the insertion allele of DHFRc.594 + 59del19bp polymorphisms 
may result in intracranial aneurysm formation [5]. The G-allele of the missense 
polymorphism Tc2c.777C→G may protect from the development of intracranial 
aneurysm [5]. This G-allele of the Tc2c.777C→G polymorphism has been reported 
to affect the vitamin B12 binding affinity and the ability to transport vitamin B12 
into tissues [5, 24–26]. This causes a decrease in remethylation of homocysteine to 
methionine by vitamin B12-dependent MTR [5, 24–26].
4. Role of nitric oxide in homocysteine metabolism
Impairment of homocysteine metabolism may lead to an accumulation of 
asymmetric dimethylarginine [27, 28]. Asymmetric dimethylarginine.is a major 
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endogenous inhibitor of nitric oxide (NO) and is a good predictor of early car-
diovascular diseases and mortality [27–30]. In addition, the availability of NO is a 
major requirement for the development of intracranial aneurysms [5, 31].
In an animal study conducted in rodents, the development of intracranial aneu-
rysm was prevented by inhibition of nitric oxide synthase (NOS) [5, 31]. Inducible 
nitric oxide synthase (iNOS) is expressed in human and rat cerebral aneurysms [2]. 
In another animal study, the size of intracranial aneurysms is significantly smaller 
in the mice with iNOS compared to the mice without iNOS [2, 5].
Aminoguanidine is a relatively selective inhibitor of iNOS [2]. Aminoguanidine 
reduces the number of the aneurysms in rats [2]. In the study by Sadamasa et al., 
iNOS possibly has management potential in the prevention of the progression of 
cerebral aneurysms, though it is not necessary for the initiation of cerebral aneu-
rysm [2].
However, in another study, there was no association between homocysteine and 
intracranial aneurysms. Notably, this study was conducted comparing a case group 
(patients with intracranial aneurysms) with a control group consisting of patients 
with arteriovenous malformation (AVM) as well as no aneurysms [14].
5. Management
Raised serum homocysteine can be properly managed with dietary changes 
[17]. An increase in serum homocysteine can be treated by folic acid, vitamin B12 
and vitamin B6 supplements [13, 15]. Folic acid and vitamin B12 supplements can 
prevent the development and progression of intracranial aneurysm [17].
6. Conclusion
In conclusion, we believe that there is association between raised serum 
homocysteine and development or progression of intracranial aneurysms. In 
the future, more case-control research studies can be conducted to compare the 
patients with intracranial aneurysms and patients without intracranial aneu-
rysms and AVM.
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